Bullous pyoderma gangrenosum

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:538869L88
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Bullous pyoderma gangrenosum (also called bullous PG) is a rare and painful skin condition that belongs to a group of disorders called neutrophilic dermatoses. This means the immune system sends too many white blood cells called neutrophils to the skin, causing severe inflammation and damage. In the bullous form, the skin develops large fluid-filled blisters (called bullae) that can break open and turn into deep, painful ulcers (open sores). These sores most often appear on the arms, legs, and face, but can occur anywhere on the body. Bullous pyoderma gangrenosum is considered a subtype of pyoderma gangrenosum (PG). What makes the bullous type unique is that the blisters tend to be more superficial and spread quickly, and it is strongly linked to blood disorders such as myeloid leukemia and myelodysplastic syndrome. The skin can be extremely sensitive — even minor bumps or injuries can trigger new sores, a reaction called pathergy. Treatment focuses on calming the overactive immune system. Doctors often use corticosteroids like prednisone as a first step, along with other immune-suppressing medicines such as cyclosporine, dapsone, or colchicine. Wound care is also very important to prevent infection and help healing. Because this condition is often linked to an underlying blood disorder, treating that underlying disease is a key part of managing bullous PG.

Also known as:

Key symptoms:

Large fluid-filled blisters on the skinPainful open sores or ulcers that develop from broken blistersSores that spread quickly and have irregular, ragged edgesSkin that is very sensitive — minor injuries can trigger new soresRedness and swelling around the soresSores that may ooze or bleedFever and feeling generally unwell during flare-upsScarring after sores healSores most commonly on the arms, legs, and face

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Bullous pyoderma gangrenosum.

View clinical trials →

No actively recruiting trials found for Bullous pyoderma gangrenosum at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Bullous pyoderma gangrenosum community →

No specialists are currently listed for Bullous pyoderma gangrenosum.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Bullous pyoderma gangrenosum.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Bullous pyoderma gangrenosumForum →

No community posts yet. Be the first to share your experience with Bullous pyoderma gangrenosum.

Start the conversation →

Latest news about Bullous pyoderma gangrenosum

No recent news articles for Bullous pyoderma gangrenosum.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Do I need to be tested for an underlying blood disorder, and if so, which tests should I have?,What treatment do you recommend first, and how long before I should expect to see improvement?,How should I care for my wounds at home, and what dressings are safest to use?,What signs of infection or worsening should prompt me to go to the emergency room?,Are there clinical trials or newer treatments I should know about?,How often will I need blood tests to monitor my medications?,Will treating an underlying blood disorder help my skin condition improve?

Common questions about Bullous pyoderma gangrenosum

What is Bullous pyoderma gangrenosum?

Bullous pyoderma gangrenosum (also called bullous PG) is a rare and painful skin condition that belongs to a group of disorders called neutrophilic dermatoses. This means the immune system sends too many white blood cells called neutrophils to the skin, causing severe inflammation and damage. In the bullous form, the skin develops large fluid-filled blisters (called bullae) that can break open and turn into deep, painful ulcers (open sores). These sores most often appear on the arms, legs, and face, but can occur anywhere on the body. Bullous pyoderma gangrenosum is considered a subtype of py

How is Bullous pyoderma gangrenosum inherited?

Bullous pyoderma gangrenosum follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Bullous pyoderma gangrenosum typically begin?

Typical onset of Bullous pyoderma gangrenosum is adult. Age of onset can vary across affected individuals.